


# **ONETOUCH® PING® SALES AID iPAD® APP B**

OneTouch® Ping®


**ONETOUCH® | DDB° Remedy**

## THE 2 PATHWAYS



## **PORTFOLIO (ACCESSIBLE AT ALL TIMES)**

## ACCESS (ACCESSIBLE AT ALL TIMES)




As the app loads, the People for Pumping images pop in, forming a grid of faces all around the OT Ping logo.

TBD-images appear to flip out from the background.

The resolve screen—hold for a second and then transition automatically to next screen.

## **ONETOUCH® PING® SALES AID PING A (LIFESTYLE)**





## ISSUE SCREEN

Clicking on either of the center images flips it around to reveal the issue associated with that patient type.

The user has selected the girl.


This leads to the "Lifestyle" story, Ping A.



## INTRO SCREEN

Open on the headline. The meter and pump move in from either side of the screen, and hold for a second.


They then swiftly move to the center, hold for a short beat, then zip back to the sides....



## INTRO



... the second stage of the headline is revealed.

Swipe to the next screen.

**BENEFIT SCREEN**

Open on the overhead group of meters. User can tap each numbered circle to display the 5 big advantages.

Callouts can only appear on-screen one at a time.



**5 big advantages  
of pump therapy  
compared with  
multiple daily injections.**

1  
2 Reduced glycemic variability<sup>1,2</sup>  
3  
4  
5

**ONETOUCH®**

BENEFIT SCREEN-continued

1. Hoogma RPLM, Hammond PJ, Gomis R, et al. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycemic control and quality of life: results of the 5-nations trial. *Diabet Med*. 2005;23(2):141-147. 2. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomized controlled trials. *BMJ*. 2002;324(7339):705+.

2 Reduced glycemic variability<sup>1,2</sup>



**5 big advantages  
of pump therapy  
compared with  
multiple daily injections.**

1  
2  
3 Reduced severe hypoglycemia<sup>1-5</sup>  
4  
5

**ONETOUCH®**

1. Rudolph JW, Hirsch IB. Assessment of therapy with continuous subcutaneous insulin infusion in an academic diabetes clinic. *Endocr Pract*. 2002;8(6):401-405. 2. Hoogma RPLM, Hammond PJ, Gomis R, et al. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycemic control and quality of life: results of the 5-nations trial. *Diabet Med*. 2005;23(2):141-147. 3. Linkeschova R, Raoul M, Bott U, Berger M, Spraul M. Less severe hypoglycemia, better metabolic control, and improved quality of life in type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. *Diabet Med*. 2002;19(9):746-751. 4. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. *Diabetes Care*. 1996;19(4):324-327. 5. Bode BW, Sabbah HT, Gross TM, Frederickson LP, Davidson PC. Diabetes management in the new millennium using insulin pump therapy. *Diabetes Metab Res Rev*. 2002;18(suppl 1):S14-S20.

3 Reduced severe hypoglycemia<sup>1-5</sup>



BENEFIT SCREEN-continued

OneTouch® Ping®.  
Lifestyle performance.

Discreet diabetes management

Accurate carb counting

Outstanding readability

Uninterrupted insulin delivery\*

The OneTouch® Ping® insulin pump is tested and proven waterproof at 12 feet for 24 hours. The meter-remote must not be exposed to water.

ONE TOUCH

HOME ACCESS PORTFOLIO

OneTouch® Ping®.  
Lifestyle performance.

Discreet diabetes management

Accurate carb counting

Outstanding readability

Uninterrupted insulin delivery\*

Bolus via meter-remote

The OneTouch® Ping® insulin pump is tested and proven waterproof at 12 feet for 24 hours. The meter-remote must not be exposed to water.

ONE TOUCH

HOME ACCESS PORTFOLIO

## LIFESTYLE FEATURES

Each callout is generated by tapping on the buttons to the left of the Ping system.

Only one callout can be open at a time.

Tap right arrow to go to next screen at any point.

OneTouch® Ping®.  
Lifestyle performance.

Discreet diabetes management  
Accurate carb counting  
Outstanding readability  
Uninterrupted insulin delivery\*

Built-in CalorieKing™ food database in meter-remote

\*The OneTouch® Ping® insulin pump is tested and proven waterproof at 12 feet for 24 hours. The meter-remote must not be exposed to water.

ONETOUCH®

OneTouch® Ping®.  
Lifestyle performance.

Discreet diabetes management  
Accurate carb counting  
Outstanding readability  
Uninterrupted insulin delivery\*

For patients with low vision<sup>1</sup>

\*The OneTouch® Ping® insulin pump is tested and proven waterproof at 12 feet for 24 hours. The meter-remote must not be exposed to water.

ONETOUCH®

LIFESTYLE FEATURES-continued

**OneTouch® Ping®.**  
Lifestyle performance.

**Discreet diabetes management**

**Accurate carb counting**

**Outstanding readability**

**Uninterrupted insulin delivery\***



**Waterproof pump\***

\*The OneTouch® Ping® insulin pump is tested and proven waterproof at 12 feet for 24 hours. The meter-remote must not be exposed to water.

**ONETOUCH®**

**OneTouch® Ping®.**  
Lifestyle performance.

**Discreet diabetes management**

**Accurate carb counting**

**Outstanding readability**

**Uninterrupted insulin delivery\***



**For patients with low vision<sup>1</sup>**

1. Burton DM, Uslan MM, Blubaugh MV, Clements CW 3rd. Are current insulin pumps accessible to blind and visually impaired people? *J Diabetes Sci Technol.* 2009;3(3):613-618.

\*The OneTouch® Ping® insulin pump is tested and proven waterproof at 12 feet for 24 hours. The meter-remote must not be exposed to water.

**ONETOUCH®**

LIFESTYLE FEATURES-continued

LIFESTYLE FEATURES-references pop-up

**OneTouch® Ping®.**  
Clinical performance.

Better accuracy per basal delivery\*

Fine-tuned control

Postprandial control††

DoubleSure™ Technology



**ONETOUCH®**

\*Bench data: Dose-to-Dose Variability Characterization of Durable and Disposable Insulin Infusion Pumps, analysis presented at the Advanced Technologies & Treatments for Diabetes 2012 conference. Study conducted using OneTouch® Ping® versus other leading pumps, including Medtronic MiniMed Paradigm® Revel™/Neo™, Roche ACCU-CHEK® Combo, and Insulet OmniPod®. The OmniPod® system that was assessed was the prior-generation system (versus the new OmniPod® system). ††Twenty-four patients with type 1 diabetes used the bolus calculators from the Animas® 2020, MiniMed Paradigm®, and Roche Combo insulin pump systems to correct postprandial hyperglycemia. The Animas® 2020 bolus calculator algorithm is identical to the OneTouch® Ping® calculator.

**CLINICAL FEATURES**

Each callout is generated by tapping on the buttons to the left of the Ping system.

Only one callout can be open at a time.

Tap right arrow to go to next screen at any point.

**OneTouch® Ping®.**  
Clinical performance.

Better accuracy per basal delivery\*

Fine-tuned control

Postprandial control††

DoubleSure™ Technology



**ONETOUCH®**

\*Bench data: Dose-to-Dose Variability Characterization of Durable and Disposable Insulin Infusion Pumps, analysis presented at the Advanced Technologies & Treatments for Diabetes 2012 conference. Study conducted using OneTouch® Ping® versus other leading pumps, including Medtronic MiniMed Paradigm® Revel™/Neo™, Roche ACCU-CHEK® Combo, and Insulet OmniPod®. The OmniPod® system that was assessed was the prior-generation system (versus the new OmniPod® system). ††Twenty-four patients with type 1 diabetes used the bolus calculators from the Animas® 2020, MiniMed Paradigm®, and Roche Combo insulin pump systems to correct postprandial hyperglycemia. The Animas® 2020 bolus calculator algorithm is identical to the OneTouch® Ping® calculator.

**Superior accuracy per basal delivery vs. Medtronic, Roche, and OmniPod® in a study comparing dose-to-dose variability<sup>1\*</sup>**

**Details**

**ONETOUCH®**

1. Capurro J, Jahn L. Comparative dose-to-dose variability analysis of durable and disposable insulin pumps. Paper given at the Advanced Technologies & Treatments for Diabetes Meeting in February 2012.

**Superior accuracy per basal delivery vs. Medtronic, Roche, and OmniPod® in a study comparing dose-to-dose variability<sup>1\*</sup>**

**CLINICAL FEATURES-REFERENCE**

**OneTouch® Ping®.**  
Clinical performance.

Better accuracy per basal delivery\*

Fine-tuned control

Postprandial control†‡

DoubleSure™ Technology

The only insulin pump to deliver basal insulin in 0.025 U/hr increments across all available rates (0.025 U/hr–25 U/hr)

**ONETOUCH®**

\*Bench data: Dose-to-Dose Variability Characterization of Durable and Disposable Insulin Infusion Pumps, analysis presented at the Advanced Technologies & Treatments for Diabetes 2012 conference. Study conducted using OneTouch® Ping® versus other leading pumps, including Medtronic MiniMed Paradigm® Revel™/Neo™, Roche ACCU-CHEK® Combo, and Insulet OmniPod®. The OmniPod® system that was assessed was the prior-generation system (versus the new OmniPod® system). †Twenty-four patients with type 1 diabetes used the bolus calculators from the Animas® 2020, MiniMed Paradigm®, and Roche Combo insulin pump systems to correct postprandial hyperglycemia. The Animas® 2020 bolus calculator algorithm is identical to the OneTouch® Ping® calculator.

**OneTouch® Ping®.**  
Clinical performance.

Better accuracy per basal delivery\*

Fine-tuned control

Postprandial control†‡

DoubleSure™ Technology

Superior bolus calculator† at achieving postprandial control vs. Medtronic Paradigm® Bolus Wizard®<sup>‡</sup>

**ONETOUCH®**

\*Bench data: Dose-to-Dose Variability Characterization of Durable and Disposable Insulin Infusion Pumps, analysis presented at the Advanced Technologies & Treatments for Diabetes 2012 conference. Study conducted using OneTouch® Ping® versus other leading pumps, including Medtronic MiniMed Paradigm® Revel™/Neo™, Roche ACCU-CHEK® Combo, and Insulet OmniPod®. The OmniPod® system that was assessed was the prior-generation system (versus the new OmniPod® system). †Twenty-four patients with type 1 diabetes used the bolus calculators from the Animas® 2020, MiniMed Paradigm®, and Roche Combo insulin pump systems to correct postprandial hyperglycemia. The Animas® 2020 bolus calculator algorithm is identical to the OneTouch® Ping® calculator.

## CLINICAL FEATURES-CONTINUED

Superior bolus calculator† at achieving postprandial control vs. Medtronic Paradigm® Bolus Wizard®<sup>‡</sup>

- Zisser H, Wagner R, Pleus S, et al. Clinical performance of three bolus calculators in subjects with type 1 diabetes mellitus: a head-to-head-to-head comparison. *Diabetes Technol Ther.* 2010;12(12):955-961.



## CLINICAL FEATURES-REFERENCE

The screenshot shows a mobile application interface. At the top, there are three navigation buttons: "HOME" (grey), "ACCESS" (blue), and "PORTFOLIO" (light blue). Below this, the text "OneTouch® Ping®. Clinical performance." is displayed. To the left, four yellow callout boxes list features: "Better accuracy per basal delivery\*", "Fine-tuned control", "Postprandial control†‡", and "DoubleSure™ Technology". To the right, a blue box contains the text "ONE TOUCH Ultra® Test Strips Blue" and "100 Test Strips". It also features a small image of a test strip and the "DoubleSure Technology" logo. A yellow arrow points from the "DoubleSure Technology" callout to this text. Below the box, the text "Proven Accuracy" and "For blood glucose testing with the OneTouch® Ultra® Family of Meters and the OneTouch® Ping® Meter Remote." is shown. At the bottom of the screen, there is a note about bench data and a disclaimer about postprandial control.

Bench data: Dose-to-Dose Variability Characterization of Durable and Disposable Insulin Infusion Pumps, analysis presented at the Advanced Technologies & Treatments for Diabetes 2012 conference. Study conducted using OneTouch® Ping® versus other leading pumps, including Medtronic MiniMed Paradigm® Revel™/Neo™, Roche ACCU-CHEK® Combo, and Insulet OmniPod®. The OmniPod® system that was assessed was the prior-generation system (versus the new OmniPod® system).

†‡Twenty-four patients with type 1 diabetes used the bolus calculators from the Animas® 2020, MiniMed Paradigm®, and Roche Combo insulin pump systems to correct postprandial hyperglycemia. The Animas® 2020 bolus calculator algorithm is identical to the OneTouch® Ping® calculator.

## CLINICAL FEATURES-CONTINUED




CLOSE SCREEN

Open on picture of patient. Tapping image flips it around to reveal the CTA.


The People for Pumping headshots return to the sides of the screen.

## **ONETOUCH® PING® SALES AID PING B (CLINICAL)**




## ISSUE SCREEN

Clicking on either of the center images flips it around to reveal the issue associated with that patient type.




The user has selected the middle-aged man.

This leads to the "Clinical performance" story, Ping B.




## INTRO SCREEN

Open on the headline. The meter and pump move in from either side of the screen, and hold for a second.



They then swiftly move to the center, hold for a short beat, then zip back to the sides....



... revealing the second stage of the headline.

Tap right arrow to go to next screen.

**OneTouch® Ping®.**  
Clinical performance.

Better accuracy per basal delivery\*

Fine-tuned control

Postprandial control†‡

DoubleSure™ Technology

**ONETOUCH®**

\*Bench data: Dose-to-Dose Variability Characterization of Durable and Disposable Insulin Infusion Pumps, analysis presented at the Advanced Technologies & Treatments for Diabetes 2012 conference. Study conducted using OneTouch® Ping® versus other leading pumps, including Medtronic MiniMed Paradigm® Revel™/Veo™, Roche ACCU-CHEK® Combo, and Insulet OmniPod®. The OmniPod® system that was assessed was the prior-generation system (versus the new OmniPod® system). †Twenty-four patients with type 1 diabetes used the bolus calculators from the Animas® 2020, MiniMed Paradigm®, and Roche Combo insulin pump systems to correct postprandial hyperglycemia. The Animas® 2020 bolus calculator algorithm is identical to the OneTouch® Ping® calculator.

**CLINICAL FEATURES**

Same as Ping A, except with button leading to charts as noted. TBD.

Tap right arrow to go to next screen at any point.

\*Bench data: Dose-to-Dose Variability Characterization of Durable and Disposable Insulin Infusion Pumps, analysis presented at the Advanced Technologies & Treatments for Diabetes 2012 conference. Study conducted using OneTouch® Ping® versus other leading pumps, including Medtronic MiniMed Paradigm® Revel™/Veo™, Roche ACCU-CHEK® Combo, and Insulet OmniPod®. The OmniPod® system that was assessed was the prior-generation system (versus the new OmniPod® system). †Twenty-four patients with type 1 diabetes used the bolus calculators from the Animas® 2020, MiniMed Paradigm®, and Roche Combo insulin pump systems to correct postprandial hyperglycemia. The Animas® 2020 bolus calculator algorithm is identical to the OneTouch® Ping® calculator.

**OneTouch® Ping®.**  
Clinical performance.

Better accuracy per basal delivery\*

Fine-tuned control

Postprandial control†‡

DoubleSure™ Technology

Superior accuracy per basal delivery vs. Medtronic, Roche, and OmniPod® in a study comparing dose-to-dose variability†\*

**ONETOUCH®**

\*Bench data: Dose-to-Dose Variability Characterization of Durable and Disposable Insulin Infusion Pumps, analysis presented at the Advanced Technologies & Treatments for Diabetes 2012 conference. Study conducted using OneTouch® Ping® versus other leading pumps, including Medtronic MiniMed Paradigm® Revel™/Veo™, Roche ACCU-CHEK® Combo, and Insulet OmniPod®. The OmniPod® system that was assessed was the prior-generation system (versus the new OmniPod® system). †Twenty-four patients with type 1 diabetes used the bolus calculators from the Animas® 2020, MiniMed Paradigm®, and Roche Combo insulin pump systems to correct postprandial hyperglycemia. The Animas® 2020 bolus calculator algorithm is identical to the OneTouch® Ping® calculator.

B only: Button underneath callout takes user to the Dose-to-Dose chart screen.  
(Chart screens can be seen at the end of this section.)

**REFERENCE POP-UP**

1. Capurro J, Jahn L. Comparative dose-to-dose variability analysis of durable and disposable insulin pumps. Paper given at the Advanced Technologies & Treatments for Diabetes Meeting in February 2012.

**Superior accuracy per basal delivery vs. Medtronic, Roche, and OmniPod® in a study comparing dose-to-dose variability†\***

**OneTouch® Ping®.**  
Clinical performance.

Better accuracy per basal delivery\*

Fine-tuned control

Postprandial control††

DoubleSure™ Technology

The only insulin pump to deliver basal insulin in 0.025 U/hr increments across all available rates (0.025 U/hr–25 U/hr)

**ONETOUCH®**

\*Bench data: Dose-to-Dose Variability Characterization of Durable and Disposable Insulin Infusion Pumps, analysis presented at the Advanced Technologies & Treatments for Diabetes 2012 conference. Study conducted using OneTouch® Ping® versus other leading pumps, including Medtronic MiniMed Paradigm® Revel™/Neo™, Roche ACCU-CHEK® Combo, and Insulet OmniPod®. The OmniPod® system that was assessed was the prior-generation system (versus the new OmniPod® system). ††Twenty-four patients with type 1 diabetes used the bolus calculators from the Animas® 2020, MiniMed Paradigm®, and Roche Combo insulin pump systems to correct postprandial hyperglycemia. The Animas® 2020 bolus calculator algorithm is identical to the OneTouch® Ping® calculator.

**OneTouch® Ping®.**  
Clinical performance.

Better accuracy per basal delivery\*

Fine-tuned control

Postprandial control††

DoubleSure™ Technology

Superior bolus calculator† at achieving postprandial control vs. Medtronic Paradigm® Bolus Wizard®<sup>†</sup>

**ONETOUCH®**

\*Bench data: Dose-to-Dose Variability Characterization of Durable and Disposable Insulin Infusion Pumps, analysis presented at the Advanced Technologies & Treatments for Diabetes 2012 conference. Study conducted using OneTouch® Ping® versus other leading pumps, including Medtronic MiniMed Paradigm® Revel™/Neo™, Roche ACCU-CHEK® Combo, and Insulet OmniPod®. The OmniPod® system that was assessed was the prior-generation system (versus the new OmniPod® system). †Twenty-four patients with type 1 diabetes used the bolus calculators from the Animas® 2020, MiniMed Paradigm®, and Roche Combo insulin pump systems to correct postprandial hyperglycemia. The Animas® 2020 bolus calculator algorithm is identical to the OneTouch® Ping® calculator.

## CLINICAL FEATURES

Same as Ping A.

Tap right arrow to go to next screen at any point.

B only: Button underneath callout takes user to the Bolus Delivery chart screen.  
(Chart screens can be seen at the end of this section.)

## REFERENCE POP-UP

**Superior bolus calculator† at achieving postprandial control vs. Medtronic Paradigm® Bolus Wizard®<sup>†</sup>**

1. Zisser H, Wagner R, Pleus S, et al. Clinical performance of three bolus calculators in subjects with type 1 diabetes mellitus: a head-to-head-to-head comparison. *Diabetes Technol Ther.* 2010;12(12):955-961.

The screenshot shows a mobile application interface for the OneTouch Ping Sales Aid. At the top, there are three navigation buttons: "HOME" (grey), "ACCESS" (blue), and "PORTFOLIO" (light blue). Below this, the text "OneTouch® Ping®. Clinical performance." is displayed. To the left, four yellow callout boxes list features: "Better accuracy per basal delivery\*", "Fine-tuned control", "Postprandial control†", and "DoubleSure™ Technology". To the right, a box contains an image of "ONE TOUCH Ultra® Test Strips Blue" with "100 Test Strips". A callout arrow points from the "DoubleSure™ Technology" box to the "DoubleSure™ Technology" logo on the test strip box. Below the test strip box, text reads: "OneTouch® Ultra® Blue Test Strips have DoubleSure™ Technology, which automatically checks each blood sample twice to confirm the result." At the bottom of the screen, there is a "ONE TOUCH" logo.

Better accuracy per basal delivery\*

Fine-tuned control

Postprandial control†

DoubleSure™ Technology

ONE TOUCH Ultra® Test Strips Blue  
100 Test Strips  
DoubleSure™ Technology  
Proven Accuracy  
For blood glucose testing with the OneTouch® Ultra® Family of Meters and the OneTouch® Ping® Meter Remote.

OneTouch® Ultra® Blue Test Strips have DoubleSure™ Technology, which automatically checks each blood sample twice to confirm the result.

\*Bench data: Dose-to-Dose Variability Characterization of Durable and Disposable Insulin Infusion Pumps, analysis presented at the Advanced Technologies & Treatments for Diabetes 2012 conference. Study conducted using OneTouch® Ping® versus other leading pumps, including Medtronic MiniMed Paradigm® Revel™/Neo™, Roche ACCU-CHEK® Combo, and Insulet OmniPod®. The OmniPod® system that was assessed was the prior-generation system (versus the new OmniPod® system).  
†Twenty-four patients with type 1 diabetes used the bolus calculators from the Animas® 2020, MiniMed Paradigm®, and Roche Combo insulin pump systems to correct postprandial hyperglycemia. The Animas® 2020 bolus calculator algorithm is identical to the OneTouch® Ping® calculator.

**OneTouch® Ping® demonstrates superior accuracy per delivery of basal insulin versus the Medtronic MiniMed Paradigm® Revel™/Veo™ pump, Roche ACCU-CHEK® Combo pump, and Insulet OmniPod® pump.<sup>1†</sup>**

**OneTouch® Ping® vs.**

MEDTRONIC MINIMED PARADIGM® REVEL™/VEO™  
ROCHE ACCU-CHEK® COMBO  
INSULET OMNIPOD®

**DOSE-TO-DOSE VARIABILITY COMPARISON OF TYPICAL PUMP<sup>‡</sup> PERFORMANCE**

All pumps in the study were programmed to deliver a basal rate of 0.5 U/hr over 20 hours, with the Insulet OmniPod® pump delivering 0.05 U basal doses every 6 minutes while the other three pumps delivered 0.025 U basal doses every 3 minutes.

Thirty data sets were assessed. In total, 5,977 doses, 12,000 doses, 11,987 doses, and 11,947 doses were delivered for Insulet OmniPod®, OneTouch® Ping®, Medtronic MiniMed Paradigm® Revel™/Veo™, and Roche ACCU-CHEK® Combo pumps, respectively.

\*A combination of two Medtronic MiniMed Paradigm® Revel™ and four Veo™ pumps were assessed. The Paradigm® Veo™ pump is available for sale in select markets outside the U.S.  
†Bench data: Dose-to-Dose Variability Characterization of Durable and Disposable Insulin Infusion Pumps, analysis presented at the Advanced Technologies & Treatments for Diabetes 2012 conference. Study conducted using OneTouch® Ping® versus other leading pumps, including Medtronic MiniMed Paradigm® Revel™/Veo™, Roche ACCU-CHEK® Combo, and Insulet OmniPod®. The OmniPod® system that was assessed was the prior-generation system (versus the new OmniPod® system).  
‡For each manufacturer, the "typical pump" is the data set with the median standard deviation in dose percent error.

**ONETOUCH®**

Thirty data sets were assessed. In total, 5,977 doses, 12,000 doses, 11,987 doses, and 11,947 doses were delivered for Insulet OmniPod®, OneTouch® Ping®, Medtronic MiniMed Paradigm® Revel™/Veo™, and Roche ACCU-CHEK® Combo pumps, respectively.

1. Capurro J, Jahn L. Comparative dose-to-dose variability analysis of durable and disposable insulin pumps. Paper given at the Advanced Technologies & Treatments for Diabetes Meeting in February 2012.

\*A combination of two Medtronic MiniMed Paradigm® Revel™ and four Veo™ pumps were assessed. The Paradigm® Veo™ pump is available for sale in select markets outside the U.S.  
†Bench data: Dose-to-Dose Variability Characterization of Durable and Disposable Insulin Infusion Pumps, analysis presented at the Advanced Technologies & Treatments for Diabetes 2012 conference. Study conducted using OneTouch® Ping® versus other leading pumps, including Medtronic MiniMed Paradigm® Revel™/Veo™, Roche ACCU-CHEK® Combo, and Insulet OmniPod®. The OmniPod® system that was assessed was the prior-generation system (versus the new OmniPod® system).  
‡For each manufacturer, the "typical pump" is the data set with the median standard deviation in dose percent error.

**BASAL DELIVERY CHARTS**

Tap any of the 3 left buttons to generate charts.

Tap the left navigation button to return to the Clinical Performance screen.

**REFERENCE POP-UP**

**OneTouch® Ping® demonstrates superior accuracy per delivery of basal insulin versus the Medtronic MiniMed Paradigm® Revel™/Veo™ pump, Roche ACCU-CHEK® Combo pump, and Insulet OmniPod® pump.<sup>1†</sup>**

**OneTouch® Ping® vs.**

MEDTRONIC MINIMED PARADIGM® REVEL™/VEO™  
ROCHE ACCU-CHEK® COMBO  
INSULET OMNIPOD®

**DOSE-TO-DOSE VARIABILITY COMPARISON OF TYPICAL PUMP<sup>‡</sup> PERFORMANCE**

**OneTouch® Ping® vs. Medtronic MiniMed Paradigm® Revel™/Veo™**

All pumps in the study were programmed to deliver a basal rate of 0.5 U/hr over 20 hours, with the Insulet OmniPod® pump delivering 0.05 U basal doses every 6 minutes while the other three pumps delivered 0.025 U basal doses every 3 minutes.

Thirty data sets were assessed. In total, 5,977 doses, 12,000 doses, 11,987 doses, and 11,947 doses were delivered for Insulet OmniPod®, OneTouch® Ping®, Medtronic MiniMed Paradigm® Revel™/Veo™, and Roche ACCU-CHEK® Combo pumps, respectively.

Cumulative doses within ±10% accuracy threshold for all 30 data sets  
86% OneTouch® Ping®  
73% Medtronic Revel™/Veo™  
p=0.0009

**ONETOUCH®**

\*A combination of two Medtronic MiniMed Paradigm® Revel™ and four Veo™ pumps were assessed. The Paradigm® Veo™ pump is available for sale in select markets outside the U.S.  
†Bench data: Dose-to-Dose Variability Characterization of Durable and Disposable Insulin Infusion Pumps, analysis presented at the Advanced Technologies & Treatments for Diabetes 2012 conference. Study conducted using OneTouch® Ping® versus other leading pumps, including Medtronic MiniMed Paradigm® Revel™/Veo™, Roche ACCU-CHEK® Combo, and Insulet OmniPod®. The OmniPod® system that was assessed was the prior-generation system (versus the new OmniPod® system).  
‡For each manufacturer, the "typical pump" is the data set with the median standard deviation in dose percent error.

**PING VS. MEDTRONIC**

All text appears at once.

The blue Ping line draws in first, from left to right, followed by the gray competitor line.



## PING VS. ACCU-CHEK

All text appears at once.

The blue Ping line draws in first, from left to right, followed by the gray competitor line.

## PING VS. OMNIPOD

All text appears at once.

The blue Ping line draws in first, from left to right, followed by the gray competitor line.

**Our bolus calculator is superior at achieving postprandial control vs. Medtronic Paradigm® Bolus Wizard®.<sup>1†</sup>**

**PROXIMITY TO TARGET** **TIME WITHIN TARGET**



**Automated bolus calculator technology that excels.**

The bolus calculator in OneTouch® Ping® corrects to the midpoint of the programmed target blood glucose range. The Medtronic Paradigm® Bolus Wizard® corrects to the outer limits of the target. This can impact the amount of insulin recommended and whether or not a correction is recommended.<sup>1\*</sup>

\*Medtronic Paradigm® Bolus Wizard® feature information from Medtronic MiniMed Paradigm® Revel™ User Guide and Zisser H, Wagner R, Pleus S, et al. Diabetes Technol Ther. 2010;12(12):955-961.  
†Twenty-four patients with type 1 diabetes used the bolus calculators from the Animas® 2020, MiniMed Paradigm®, and Roche Combo insulin pump systems to correct postprandial hyperglycemia. The Animas® 2020 bolus calculator algorithm is identical to the OneTouch® Ping® calculator.


**ONETOUCH®**

**Our bolus calculator is superior at achieving postprandial control vs. Medtronic Paradigm® Bolus Wizard®.<sup>1†</sup>**

**PROXIMITY TO TARGET** **TIME WITHIN TARGET**

In a clinical study, the automated bolus calculator used in OneTouch® Ping® was shown to be more efficacious in controlling postprandial hyperglycemia than the Medtronic Paradigm® Bolus Wizard®.<sup>1†</sup> The postprandial target range for this study was set at 80 mg/dL to 140 mg/dL.

**PROXIMITY TO TARGET 6 HOURS POST-MEAL**



Category	OneTouch® Ping® (mean blood glucose)	Medtronic Paradigm® Bolus Wizard® (mean blood glucose)	Target Range (mg/dL)
Hyperglycemia	127.3 mg/dL	157.4 mg/dL	96.4 - 158.2 mg/dL
Hypoglycemia	125.6 mg/dL	125.6 mg/dL	80 - 140 mg/dL

**Postprandial blood glucose levels were significantly closer to target among patients using the bolus calculator in OneTouch® Ping® than among patients using the Medtronic Paradigm® Bolus Wizard® ( $17.3 \pm 30.9$  mg/dL vs.  $47.4 \pm 31.8$  mg/dL, respectively).<sup>1†</sup>**

**Automated bolus calculator technology that excels.**

The bolus calculator in OneTouch® Ping® corrects to the midpoint of the programmed target blood glucose range. The Medtronic Paradigm® Bolus Wizard® corrects to the outer limits of the target. This can impact the amount of insulin recommended and whether or not a correction is recommended.<sup>1\*</sup>

\*Medtronic Paradigm® Bolus Wizard® feature information from Medtronic MiniMed Paradigm® Revel™ User Guide and Zisser H, Wagner R, Pleus S, et al. Diabetes Technol Ther. 2010;12(12):955-961.  
†Twenty-four patients with type 1 diabetes used the bolus calculators from the Animas® 2020, MiniMed Paradigm®, and Roche Combo insulin pump systems to correct postprandial hyperglycemia. The Animas® 2020 bolus calculator algorithm is identical to the OneTouch® Ping® calculator.

**ONETOUCH®**


#### BOLUS CALCULATOR SCREENS-OPENING STATE

Choose from 2 charts to display.


Tap the left navigation button to return to the Clinical Performance screen.

#### PROXIMITY TO TARGET 6 HOURS POST-MEAL CHART

The axis appears first, followed by the 2 bars and associated callouts and labels.

**TIME WITHIN TARGET CHART**

The axis appears first, followed by the 2 bars and associated callouts and labels.

**REFERENCE POP-UP (CAN APPEAR WITH EITHER CHART)**

**OneTouch® Ping®.**  
Designed to meet the real-life  
needs of your patients.

**Discreet diabetes management**

**Accurate carb counting**

**Outstanding readability**

**Uninterrupted insulin delivery\***



\*The OneTouch® Ping® insulin pump is tested and proven waterproof at 12 feet for 24 hours. The meter-remote must not be exposed to water.

**ONETOUCH®**

**OneTouch® Ping®.**  
Designed to meet the real-life  
needs of your patients.

**Discreet diabetes management**

**Accurate carb counting**

**Outstanding readability**

**Uninterrupted insulin delivery\***



\*The OneTouch® Ping® insulin pump is tested and proven waterproof at 12 feet for 24 hours. The meter-remote must not be exposed to water.

**ONETOUCH®**

LIFESTYLE FEATURES-same as PING A, except for headline.

Each callout is generated by tapping on the buttons to the left of the Ping system.

Only one callout can be open at a time.

Tap right arrow to go to next screen at any point.

**OneTouch® Ping®.**  
Designed to meet the real-life  
needs of your patients.

**Discreet diabetes management**

**Accurate carb counting**

**Outstanding readability**

**Uninterrupted insulin delivery\***



Built-in CalorieKing™ food database in meter-remote

\*The OneTouch® Ping® insulin pump is tested and proven waterproof at 12 feet for 24 hours. The meter-remote must not be exposed to water.

**ONETOUCH®**

**OneTouch® Ping®.**  
Designed to meet the real-life  
needs of your patients.

**Discreet diabetes management**

**Accurate carb counting**

**Outstanding readability**

**Uninterrupted insulin delivery\***



For patients with low vision<sup>1</sup>

\*The OneTouch® Ping® insulin pump is tested and proven waterproof at 12 feet for 24 hours. The meter-remote must not be exposed to water.

**ONETOUCH®**

LIFESTYLE FEATURES-continued

**OneTouch® Ping®.**  
Designed to meet the real-life  
needs of your patients.

**Discreet diabetes management**

**Accurate carb counting**

**Outstanding readability**

**Uninterrupted insulin delivery\***

**ONE TOUCH**

\*The OneTouch® Ping® insulin pump is tested and proven waterproof at 12 feet for 24 hours. The meter-remote must not be exposed to water.

**OneTouch® Ping®.**  
Designed to meet the real-life  
needs of your patients.

**Discreet diabetes management**

**Accurate carb counting**

**Outstanding readability**

**Uninterrupted insulin delivery\***

**For patients with low vision<sup>1</sup>**


1. Burton DM, Uslan MM, Blubaugh MV, Clements CW 3rd. Are current insulin pumps accessible to blind and visually impaired people? *J Diabetes Sci Technol.* 2009;3(3):613-618.

**ONE TOUCH**

\*The OneTouch® Ping® insulin pump is tested and proven waterproof at 12 feet for 24 hours. The meter-remote must not be exposed to water.

LIFESTYLE FEATURES-continued


LIFESTYLE FEATURES-references pop-up.



DEXCOM

Page opens on both systems with button between.

Tap right arrow to go to next screen at any point.



Tapping button generates text to flow in under the Dexcom image, from top to bottom.

[HOME](#) [ACCESS](#) [PORTFOLIO](#)

**OneTouch® Ping® and Dexcom G4™ PLATINUM CGM.\***  
Two great systems each designed with patients in mind.

**Dexcom G4™ PLATINUM CGM\***

**Lifestyle flexibility**  
The transmitter can send glucose signals up to 20 feet to the receiver.<sup>1</sup>

**Smaller introducer needle**  
The sensor is inserted under the skin with an introducer needle that's over one-third smaller than Medtronic's.<sup>2,3</sup>

**7-day convenience**  
It's the only sensor FDA-approved for up to 7 days of wear.<sup>1</sup>

**Exceptional performance<sup>1</sup>**  
Exceptional hypoglycemia detection rate of 83% at 70 mg/dL.

1. Dexcom G4™ PLATINUM User Guide, 2012. 2. DiabetesHealth.com, Product Reference Guide, 2010; caliper measurements: Dexcom 0.018, Medtronic 0.028; measurements are in 1/1000th inches, May 2011. 3. Medtronic Paradigm® REAL-Time Revel™ User Guide, 2009.

[BRIEF SAFETY STATEMENT](#)

\*The Dexcom G4™ PLATINUM Continuous Glucose Monitoring System is a glucose monitoring device indicated for detecting trends and tracking patterns in persons (age 18 and older) with diabetes.

**ONTOUCH®**

**Lifestyle flexibility**  
The transmitter can send glucose signals up to 20 feet to the receiver.<sup>1</sup>

**Smaller introducer needle**  
The sensor is inserted under the skin with an introducer needle that's over one-third smaller than Medtronic's.<sup>2,3</sup>

**7-day convenience**  
It's the only sensor FDA-approved for up to 7 days of wear.<sup>1</sup>

**Exceptional performance<sup>1</sup>**  
Exceptional hypoglycemia detection rate of 83% at 70 mg/dL.

1. Dexcom G4™ PLATINUM User Guide, 2012. 2. DiabetesHealth.com, Product Reference Guide, 2010; caliper measurements: Dexcom 0.018, Medtronic 0.028; measurements are in 1/1000th inches, May 2011. 3. Medtronic Paradigm® REAL-Time Revel™ User Guide, 2009.

System is a glucose monitoring device

## DEXCOM-REFERENCES

[HOME](#) [ACCESS](#) [PORTFOLIO](#)

**OneTouch® Ping® and Dexcom G4™ PLATINUM CGM.\***  
Two great systems each designed with patients in mind.

**The Dexcom G4™ PLATINUM Continuous Glucose Monitoring System is a glucose monitoring device indicated for detecting trends and tracking patterns in persons (age 18 and older) with diabetes. CONTRAINDICATIONS: Remove the Dexcom G4™ PLATINUM System before MRI, CT scan, or diathermy treatment. Taking acetaminophen while wearing the sensor may falsely raise your sensor glucose readings. WARNING: Do not use the Dexcom G4™ PLATINUM for treatment decisions. The Dexcom G4™ PLATINUM does not replace a blood glucose meter. If a sensor breaks and no portion of it is visible above the skin, do not attempt to remove it. Seek professional medical help if you have infection or inflammation. Report broken sensors to Dexcom Technical Support. The Dexcom G4™ PLATINUM is not approved for use in children or adolescents, pregnant women or persons on dialysis. Sensor placement is not approved for sites other than under the skin of the belly (abdomen). Contact Dexcom Toll Free at 877-339-2664 or www.dexcom.com for detailed indications for use and safety information.**

[BRIEF SAFETY STATEMENT](#)

\*The Dexcom G4™ PLATINUM Continuous Glucose Monitoring System is a glucose monitoring device indicated for detecting trends and tracking patterns in persons (age 18 and older) with diabetes. CONTRAINDICATIONS: Remove the Dexcom G4™ PLATINUM System before MRI, CT scan, or diathermy treatment. Taking acetaminophen while wearing the sensor may falsely raise your sensor glucose readings. WARNING: Do not use the Dexcom G4™ PLATINUM for treatment decisions. The Dexcom G4™ PLATINUM does not replace a blood glucose meter. If a sensor breaks and no portion of it is visible above the skin, do not attempt to remove it. Seek professional medical help if you have infection or inflammation. Report broken sensors to Dexcom Technical Support. The Dexcom G4™ PLATINUM is not approved for use in children or adolescents, pregnant women or persons on dialysis. Sensor placement is not approved for sites other than under the skin of the belly (abdomen). Contact Dexcom Toll Free at 877-339-2664 or www.dexcom.com for detailed indications for use and safety information.



[BRIEF SAFETY STATEMENT](#)

\*The Dexcom G4™ PLATINUM Continuous Glucose Monitoring System is a glucose monitoring device indicated for detecting trends and tracking patterns in persons (age 18 and older) with diabetes. CONTRAINDICATIONS: Remove the Dexcom G4™ PLATINUM System before MRI, CT scan, or diathermy treatment. Taking acetaminophen while wearing the sensor may falsely raise your sensor glucose readings. WARNING: Do not use the Dexcom G4™ PLATINUM for treatment decisions. The Dexcom G4™ PLATINUM does not replace a blood glucose meter. If a sensor breaks and no portion of it is visible above the skin, do not attempt to remove it. Seek professional medical help if you have infection or inflammation. Report broken sensors to Dexcom Technical Support. The Dexcom G4™ PLATINUM is not approved for use in children or adolescents, pregnant women or persons on dialysis. Sensor placement is not approved for sites other than under the skin of the belly (abdomen). Contact Dexcom Toll Free at 877-339-2664 or www.dexcom.com for detailed indications for use and safety information.

**ONTOUCH®**

## DEXCOM-BRIEF SAFETY STATEMENT

Tapping on the Brief Safety Statement button generates pop-up. Tap pop-up to close.




CLOSE SCREEN

Function as per PING A.

# ONETOUCH® PING® SALES AID PORTFOLIO

ONETOUCH® | DDB<sup>°</sup> Remedy




## PORTFOLIO

As each product is tapped, it increases in size and a callout appears.

Tap product image again to return to this state.

The user may go the issues screen or access screen at any point using the buttons on the top of the screen.



## PING CALLOUT WITH LINK

Double-tapping the arrow within the Ping callout brings the user to the Clinical Performance screen, Ping B.



**OneTouch® is always the simple choice.**

**OneTouch® Ultra®2**  
Helps patients make the link between food and their blood glucose results.

For all of your patients' diabetes management needs, prescribe OneTouch®.

ONTOPUCH®

**OneTouch® is always the simple choice.**

**OneTouch® Verio®IQ**  
The meter that simplifies testing.

For all of your patients' diabetes management needs, prescribe OneTouch®.

ONTOPUCH®

**OneTouch® is always the simple choice.**

**OneTouch® UltraMini®**  
Sleek design that fits easily in a pocket or purse.

For all of your patients' diabetes management needs, prescribe OneTouch®.

ONTOUCH®

**OneTouch® is always the simple choice.**

**OneTouch® Delica®**  
Designed for comfortable testing—now in 2 gauge sizes (30G and 33G).

For all of your patients' diabetes management needs, prescribe OneTouch®.

ONTOUCH®

## **ONETOUCH® PING® SALES AID ACCESS**

The screenshot shows the initial screen of the app. At the top, there are 'HOME' and 'PORTFOLIO' buttons. The main text reads 'Lowest co-pay on the most health plans.\*' Below this is an image of a box of 'ONETOUCH Ultra Test Strips Blue' containing 100 strips. A yellow banner at the bottom states 'OneTouch® is always covered by Medicare Part B.†'. Small fine print at the bottom left notes that some plans may have more than one test strip covered at the lowest co-pay, and that co-insurance, deductible, and eligibility may apply.

The screenshot shows a comparison chart titled 'Your patients can save with a preferred brand, like OneTouch®.' It features three columns: 'Preferred' (with a single dollar sign icon), 'Non-formulary' (with two dollar signs icon), and 'Not covered' (with three dollar signs icon). Each column includes a brief description: 'Preferred' says 'Lowest co-pay available', 'Non-formulary' says 'On average, costs \$25 more than preferred brands', and 'Not covered' says 'Patients pay full retail price.' To the right of the chart is a small image of the same product box.

## ACCESS

Opening screen. Tap right arrow to go to next screen.

Tap right arrow to go to next screen.

**Lowest co-pay on the most health plans.\***

<Plan Name>	OneTouch® Ultra®	Bayer	Abbott	Roche
<Plan Name>				

\*Some plans may have more than one test strip covered at the lowest co-pay.

**ONETOUCH®**

The rep can select up to 4 products across the top, and up to 5 plans along the left side.

**Lowest co-pay on the most health plans.\***

<Plan Name>	OneTouch® Ultra®	Bayer	Abbott	Roche
<Plan Name>	\$	\$\$	\$\$\$	\$
<Plan Name>				
<Plan Name>	\$	\$\$	\$\$\$	\$\$
<Plan Name>				
<Plan Name>	\$	\$\$	\$\$\$	\$\$
<Plan Name>	\$	\$\$	\$\$\$	\$\$
<Plan Name>	\$	\$\$	\$\$\$	\$\$
<Plan Name>				
<Plan Name>				

\$ Preferred    \$\$ Non-formulary    \$\$\$ Not covered

\*Some plans may have more than one test strip covered at the lowest co-pay.

**ONETOUCH®**

Each row then fills in with access information.